Instrument Inactif

Autres langues PHARMING GROUP Euronext Amsterdam

Actions

NL0000377018

Produits pharmaceutiques

Cours en clôture Euronext Amsterdam
- ^EUR	-

15:24	Pharming dévoile des données de Phase II positives pour le Leniolisib
08:06	Pharming Group N.V. annonce des données intermédiaires positives de phase II pour le leniolisib dans des DIPs avec dérégulation immunitaire, acceptées en communication de dernière minute à l’ESID 2026	CI

Autres langues

09:04	Pharming meldt goed nieuws voor Joenja
08:06	Pharming Group N.V. Announces Positive Phase II Topline Data For Leniolisib In PIDs With Immune Dysregulation Accepted As Late-Breaking Abstract At ESID 2026
07:13	Pharming presenteert spoedig nieuwe studieresultaten met leniolisib
07:00	Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
14/09	FDA approves Pharming's Joenja(R) as first treatment for children with APDS in the U.S.
14/09	Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja
11/09	Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S
11/09	Pharming krijgt goedkeuring FDA voor nieuwe indicatie Joenja
11/09	FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
11/09	Pharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11
11/09	Pharming krijgt goedkeuring FDA voor nieuwe indicatie Joenja
09/09	Pharming Group to participate in September investor conferences
02/09	Pharming N : Millennium International Management LP - Pharming Group N.V. - Leiden
02/09	Pharming N : Millennium International Management LP - Pharming Group N.V. - Leiden
16/08	Adyen en ABN AMRO blinken uit na cijfers
13/08	Pharming Launches Joenja in Japan for Adult, Pediatric APDS Patients
13/08	Pharming Group Launches Rare Primary Immunodeficiency Therapy Joenja in Japan
13/08	Pharming lanceert Joenja voor APDS-patiënten in Japan
13/08	Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
13/08	Pharming Group Announces Commercial Launch of Joenja in Japan for Adult and Pediatric Patients with Apds Aged 4 and Older
04/08	Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
02/08	Drukke cijferweek op Damrak kent winnaars en verliezers
30/07	Pharming Group's Q2 Earnings, Revenue Fall; 2026 Revenue Outlook Updated
30/07	Pharming Group N.V. Reports Earnings Results for the Half Year Ended June 30, 2026
30/07	Pharming stelt jaaroutlook naar beneden bij